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Functional Cloning and Characterization of the Multidrug Efflux Pumps
NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli
Abstract
Active efflux of antimicrobial agents is one of the most important adapted strategies that bacteria use to
defend against antimicrobial factors that are present in their environment. The NorM protein of Neisseria
gonorrhoeae and the YdhE protein of Escherichia coli have been proposed to be multidrug efflux pumps that
belong to the multidrug and toxic compound extrusion (MATE) family. In order to determine their
antimicrobial export capabilities, we cloned, expressed, and purified these two efflux proteins and
characterized their functions both in vivo and in vitro. E. coli strains expressing norM or ydhE showed elevated
(twofold or greater) resistance to several antimicrobial agents, including fluoroquinolones, ethidium bromide,
rhodamine 6G, acriflavine, crystal violet, berberine, doxorubicin, novobiocin, enoxacin, and
tetraphenylphosphonium chloride. When they were expressed in E. coli, both transporters reduced the levels
of ethidium bromide and norfloxacin accumulation through a mechanism requiring the proton motive force,
and direct measurements of efflux confirmed that NorM behaves as an Na+-dependent transporter. The
capacities of NorM and YdhE to recognize structurally divergent compounds were confirmed by steady-state
fluorescence polarization assays, and the results revealed that these transporters bind to antimicrobials with
dissociation constants in the micromolar region.
Disciplines
Biological and Chemical Physics | Medicinal-Pharmaceutical Chemistry | Other Chemistry
Comments
This article is from Antimicrobial Agents and Chemotherapy 52 (2008): 3052, doi:10.1128/AAC.00475-08.
Posted with permission.
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/physastro_pubs/163
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2008, p. 3052–3060 Vol. 52, No. 9
0066-4804/08/$08.000 doi:10.1128/AAC.00475-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Functional Cloning and Characterization of the Multidrug Efflux
Pumps NorM from Neisseria gonorrhoeae and YdhE
from Escherichia coli†
Feng Long,1 Corinne Rouquette-Loughlin,2 William M. Shafer,2,3 and Edward W. Yu1,4*
Molecular, Cellular, and Developmental Biology Interdepartmental Graduate Program, Iowa State University, Ames, Iowa 500111;
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 303222;
Laboratories of Microbial Pathogenesis, VA Medical Center, Decatur, Georgia 300333; and
Department of Physics and Astronomy, Iowa State University, Ames, Iowa 500114
Received 9 April 2008/Accepted 22 June 2008
Active efflux of antimicrobial agents is one of the most important adapted strategies that bacteria use to
defend against antimicrobial factors that are present in their environment. The NorM protein of Neisseria
gonorrhoeae and the YdhE protein of Escherichia coli have been proposed to be multidrug efflux pumps that
belong to the multidrug and toxic compound extrusion (MATE) family. In order to determine their antimi-
crobial export capabilities, we cloned, expressed, and purified these two efflux proteins and characterized their
functions both in vivo and in vitro. E. coli strains expressing norM or ydhE showed elevated (twofold or greater)
resistance to several antimicrobial agents, including fluoroquinolones, ethidium bromide, rhodamine 6G,
acriflavine, crystal violet, berberine, doxorubicin, novobiocin, enoxacin, and tetraphenylphosphonium chloride.
When they were expressed in E. coli, both transporters reduced the levels of ethidium bromide and norfloxacin
accumulation through a mechanism requiring the proton motive force, and direct measurements of efflux
confirmed that NorM behaves as an Na-dependent transporter. The capacities of NorM and YdhE to
recognize structurally divergent compounds were confirmed by steady-state fluorescence polarization assays,
and the results revealed that these transporters bind to antimicrobials with dissociation constants in the
micromolar region.
Neisseria gonorrhoeae is a gram-negative diplococcus which
is found only in humans and causes the sexually transmitted
disease gonorrhea. Since it is a strictly human pathogen and
can colonize male and female genital mucosal surfaces and
other sites, it has developed mechanisms to overcome host
antimicrobial systems that are important in the innate host
defense. One important mechanism that N. gonorrhoeae uses
to subvert antimicrobial agents is the expression of multidrug
efflux pumps that recognize and actively export a wide variety
of toxic (often structurally unrelated) compounds, including
antibacterial peptides, long-chain fatty acids, and several clin-
ically useful antibiotics, from the bacterial cell (17, 32, 35, 36).
Recently, four efflux pumps have been identified in N. gon-
orrhoeae. One such pump is the MtrD inner membrane protein
(21) that exists as a component of a tripartite resistance nod-
ulation cell division (RND) efflux system (41). MtrD interacts
with a periplasmic membrane fusion protein, MtrC, and an
outer membrane channel, MtrE, to mediate the export of hy-
drophobic antimicrobial agents, including antibiotics, nonionic
detergents, certain antibacterial peptides, bile salts, and go-
nadal steroidal hormones (7, 9, 10, 36). The FarB efflux pump
(17), which belongs to the major facilitator (MF) family (8, 22,
31), recognizes antibacterial long-chain fatty acids and exports
them out of the cell in conjunction with the FarA membrane
fusion protein and the MtrE outer membrane protein channel
(17). The MacB transporter was recently described (33), and it
belongs to the ATP binding cassette transporter family (13). It
is poorly expressed in wild-type gonococci due to a natural
mutation in its promoter, but it can recognize and export
certain macrolide antibiotics. Finally, N. gonorrhoeae contains
the NorM efflux pump (32), which is a member of the multi-
drug and toxic compound extrusion (MATE) family of efflux
transporters (5, 25, 32). The N. gonorrhoeae NorM transporter
is homologous to NorM of Vibrio parahaemolyticus (25), YdhE
of Escherichia coli (2, 25, 42), VmrA of V. parahaemolyticus (6),
and VcrM of Vibrio cholerae (1, 27). As a multidrug efflux
pump, the gonococcal NorM appears to recognize a number of
cationic toxic compounds, such as ethidium bromide, acrifla-
vine, 2-N-methylellipticinium, and ciprofloxacin (32). The ca-
pacity of NorM to export ciprofloxacin was suggested to be of
clinical relevance in the development of fluoroquinolone resis-
tance in N. gonorrhoeae, especially when isolates have other
mutations that raise the MIC to a level near that seen in
treatment failures.
Members of the MATE family of transporters characteris-
tically possess 12 putative transmembrane domains and have
been reported in all three kingdoms of life (Eukaryae, Ar-
chaeae, and Eubacteriae) (5). Phylogenetic tree analysis sug-
gests that this family possesses three distinct clusters: (i) the
bacterial multidrug efflux pumps, including N. gonorrhoeae
NorM and E. coli YdhE; (ii) the eukaryotic efflux proteins
found in fungi and plants, such as Erc1; and (iii) a branch
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containing E. coli DinF (5). Among these three clusters, the
putative NorM branch exhibits overall identity and similarity of
26 and 47%, respectively.
In order to directly test the capacity of the N. gonorrhoeae
NorM pump to recognize putative substrates, including cipro-
floxacin, which was, until recently, widely used in the United
States to treat gonococcal infections (15), we expressed the
gonococcal norM gene in E. coli and investigated its function
by using drug susceptibility and transport assays. We also stud-
ied the homologous protein YdhE in E. coli and compared its
function with that of N. gonorrhoeae NorM. Using a sensitive
fluorescence polarization assay (12, 18), we characterized the
interactions of these two transporters with various drugs. The
results revealed that NorM and YdhE bind to a variety of
structurally dissimilar agents in the micromolar range.
MATERIALS AND METHODS
Cloning of norM and ydhE. The norM open reading frame from the genomic
DNA of N. gonorrhoeae strain FA19 was amplified by PCR with primers 5-GAG
GAATAATAAATGCTGCTCGACCTCGACCGC-3 and 5-GTTTAAACTCAA
TGGTGATGGTGATGATGGACGGCCTTGTGTGATTTGACC-3 to generate
a product that would encode a NorM recombinant protein with a six-His tag at the
C terminus (32). The corresponding PCR product was extracted from the agarose
gel and cloned into pBAD-TOPO, as described by the manufacturer (Invitrogen).
To remove the V5 epitope and polyhistidine region of the vector, the plasmid was
digested with PmeI and then self-ligated to form the expression vector
pBADnorM. The recombinant plasmid was transformed into DH5 cells, and
transformants were selected on LB agar plates containing 100 g/ml ampicillin. The
presence of the correct norM sequence in the plasmid construct was verified by DNA
sequencing.
Similarly, the open reading frame of ydhE from E. coli K-12 genomic DNA was
amplified by PCR and TA cloned into pBAD-TOPO with primers 5-GAGGA
ATAATAAATGCAGAAGTATATCAGTG-3 and 5-GTTTAAACTCAATG
GTGATGGTGATGATG GCGGGATGCTCGTTGCAGAATG-3 to generate
a PCR product that would encode a recombinant protein containing a six-His tag
at the C terminus. The recombinant plasmid (pBADydhE) was transformed
into DH5 cells as described above, and the presence of the correct insert in a
representative plasmid transformant was verified by DNA sequencing.
Drug susceptibility assays. The MICs to various antimicrobial agents of E. coli
strains (inoculum, 104 CFU/spot) harboring pBADnorM, pBADydhE, or the
pBAD vector were determined by the twofold dilution method with LB agar
containing the desired antimicrobial agent (28). Bacterial growth was recorded
after 18 to 24 h of incubation at 37°C. Each assay was repeated at least four times
to ensure the reproducibility of the results.
Drug accumulation assays. Assays of norfloxacin and ethidium bromide ac-
cumulation were performed as described previously (20, 24, 25). In brief, E. coli
AG100AX cells carrying pBADnorM, pBADydhE, or pBAD were grown in
LB broth with 0.01% L-arabinose at 37°C to an optical density at 600 nm (OD600)
of 1.0, harvested, washed three times with buffer containing 0.1 M Tris-HCl (pH
7.0), and suspended in the same buffer to an OD600 of 1.0. Norfloxacin was then
added to a final concentration of 100 M. Samples of 1 ml were taken at
intervals, centrifuged at 10,000 rpm for 30 s at 4°C, and washed once with the
same buffer. After 15 min, carbonyl cyanide m-chlorophenylhydrazone (CCCP)
was added to a final concentration of 100 M to disrupt the proton gradient
across the membrane. Then, 15 min later, CCCP was removed by centrifugation
at 10,000 rpm for 30 s and the cells were resuspended in buffer containing 0.1 M
Tris-HCl (pH 7.0) and 0.4% glucose. Each pellet was resuspended in 1 ml of 100
mM glycine-HCl (pH 3.0), shaken vigorously for 1 h at room temperature to
release the fluorescent content, and then centrifuged at 15,000 rpm for 10 min at
room temperature. The fluorescence of the supernatants was measured at an
excitation  (ex) and an emission  (em) of 277 and 448 nm, respectively, by
using a Perkin-Elmer LS55 spectrofluorometer equipped with a Hamamatsu
R928 photomultiplier. The amount of maximum fluorescence was normalized to
100%.
For ethidium bromide accumulation, the cells were prepared in a manner
similar to that described above. To initiate the assay, ethidium bromide was
added to the cell suspension at a final concentration of 20 g/ml. Samples of 1
ml were taken at different time points. After 15 min of incubation, CCCP was
added to a final concentration of 100 M. Then, 15 min later, CCCP was
removed by centrifugation at 10,000 rpm for 30 s and the cells were resuspended
in buffer containing 0.1 M Tris-HCl (pH 7.0) and 0.4% glucose. The fluorescence
of the samples was measured at a ex and a em of 500 and 580 nm, respectively
(3). The amount of maximum fluorescence was normalized to 100%.
Accumulation of ethidium bromide in the presence of Na. E. coli AG100AX
cells containing pBADnorM or pBAD were grown in LB broth with 0.01%
L-arabinose at 37°C to an OD600 of 1.0, harvested by centrifugation, washed three
times with buffer containing 0.1 M Tris-HCl (pH 7.0), and suspended in the same
buffer to an OD600 of 1.0. Ethidium bromide was added to the cell suspension at
a final concentration of 20 g/ml, followed by the addition of 100 mM NaCl or
KCl. At each time point, a 1-ml sample was removed, centrifuged at 10,000 rpm
for 30 s at 4°C, and washed once with the same buffer. The fluorescence signal
was measured at a ex and a em of 500 and 580 nm, respectively.
Efflux of norfloxacin in the presence of Na. For the determination of nor-
floxacin efflux, cells were grown in LB broth with 0.01% L-arabinose at 37°C to
an OD600 of 1.0, harvested, and washed twice with buffer containing 0.1 M
Tris-HCl (pH 7.0). To load the cells with norfloxacin, the bacteria were incubated
in the same buffer supplemented with 100 M norfloxacin and 20 M CCCP at
37°C for 30 min, as described previously (30). The cells were then pelleted,
washed twice, and resuspended in the same buffer to an OD600 of 2.0. Samples
of 1 ml were taken at intervals, centrifuged at 10,000 rpm for 30 s at 4°C, and
washed once with the same buffer. After 10 min, NaCl or KCl was added to a
final concentration of 100 mM. Fluorescence measurement of norfloxacin was
performed by a procedure similar to that described above.
Purification of transporters. The N. gonorrhoeae NorM protein containing a
six-His tag at the C terminus was overproduced in E. coli TOP10 cells (Invitro-
gen) possessing pBADnorM. The cells were grown in 12 liters of LB medium
with 100 g/ml ampicillin at 37°C. When the OD600 reached 0.5, the culture was
treated with 0.2% L-arabinose to induce norM expression and cells were har-
vested within 3 h. The bacteria collected were resuspended, as described previ-
ously (43), in low-salt buffer containing 100 mM sodium phosphate (pH 7.2),
10% glycerol, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride (PMSF)
and were then disrupted with a French pressure cell. The membrane fraction was
collected and washed twice with a high-salt buffer containing 20 mM sodium
phosphate (pH 7.2), 2 M KCl, 10% glycerol, 1 mM EDTA, and 1 mM PMSF and
once with 20 mM HEPES–NaOH buffer (pH 7.5) containing 1 mM PMSF. The
membrane protein was then solubilized in 1% (wt/vol) n-dodecyl--D-maltoside
(DDM). Insoluble material was removed by ultracentrifugation at 370,000  g.
The extracted protein was loaded into an Ni2-affinity column; washed with a
buffer containing 20 mM HEPES–NaOH (pH 7.5), 50 mM imidazole, and 0.02%
DDM; and eluted with a buffer consisting of 20 mM HEPES–NaOH (pH 7.5),
400 mM imidazole, and 0.02% DDM. The eluted protein was then concentrated
to 5 mg/ml and loaded into G-200 sizing columns preincubated with 20 mM
HEPES–NaOH (pH 7.5) and 0.02% DDM for further purification. The YdhE
protein that contains a six-His tag at the C terminus was overproduced in E. coli
TOP10/pBADydhE and purified as described above for NorM. The purities
(	90%) of the NorM and YdhE proteins were judged by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis with Coomassie brilliant blue staining.
Fluorescence polarization assays. Fluorescence polarization assays (12, 18)
were used to determine the drug binding affinities of NorM and YdhE. The
experiments were done with a ligand binding solution containing 20 mM
HEPES–NaOH (pH 7.5), 0.02% DDM, and 1 M ligand (rhodamine 6G,
ethidium bromide, proflavine, ciprofloxacin, or norfloxacin). The protein solu-
tion, which consisted of NorM or YdhE in 20 mM HEPES–NaOH (pH 7.5),
0.02% DDM, and 1 M ligand, was titrated into the ligand binding solution until
the polarization was unchanged. As this is a steady-state approach, the fluores-
cence polarization measurement was taken after a 5-min incubation for each
corresponding concentration of the protein and drug to ensure that the binding
had reached equilibrium. It should be noted that the detergent concentration was
kept constant at all times to eliminate the change in polarization generated by
the drug-DDM micelle interaction. All measurements were performed at 25°C
with a Perkin-Elmer LS55 spectrofluorometer equipped with a Hamamatsu
R928 photomultiplier. The excitation wavelengths were 527, 483, 447, 330, and
277 nm for rhodamine 6G, ethidium, proflavine, ciprofloxacin, and norfloxacin,
respectively. Fluorescence polarization signals (as the change in polarization)
were measured at emission wavelengths of 550, 620, 508, 415, and 448 nm for
these ligands, respectively. Each titration point recorded was an average of 15
measurements. Data were analyzed by using the equation P 
 {(Pbound 
Pfree)[protein]/(KD  [protein])}  Pfree, where P is the polarization measured
at a given total protein concentration, Pfree is the initial polarization of free
ligand, Pbound is the maximum polarization of specifically bound ligand, [protein]
is the protein concentration, and KD is the dissociation constant. The titration
experiments were repeated three times to obtain the average KD value. Curve
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fitting was accomplished with the ORIGIN program (version 7.5; OriginLab
Corporation, Northampton, MA).
RESULTS AND DISCUSSION
Drug specificity of NorM and YdhE in vivo. To determine if
the N. gonorrhoeae NorM multidrug transporter is functionally
expressed in E. coli and to compare its activity to that of a second
member (YdhE) of the MATE family of efflux pumps, we trans-
formed E. coli AG100AX, an AcrAB-deficient strain (29), with
the empty pBAD vector, pBADnorM, or pBADydhE. We
then tested the susceptibilities of the representative transformants
bearing these plasmids to a panel of 24 structurally divergent
antimicrobials (Table 1). These antimicrobials were selected on
the basis of whether or not they are putative substrates of MATE
family exporters in the NorM subclass. It is important to stress
that in many instances the expression of drug efflux pumps, in-
cluding members of the MATE superfamily (5), can result in only
modest changes (twofold) in bacterial susceptibility to certain
antimicrobials, while more significant changes in susceptibility to
other agents can be observed in the same system. Indeed, in our
drug testing experiments, we detected a range of changes in the
susceptibilities of E. coli cells producing either NorM or YdhE.
Among the 24 antimicrobials tested, AG100AX cells express-
ing the N. gonorrhoeae NorM were less sensitive (two- to eight-
fold) than AG100AX cells containing pBAD to a subset of anti-
biotics (norfloxacin, doxorubicin, novobiocin, lomefloxacin,
enoxacin, and ciprofloxacin), dyes (rhodamine 6G, ethidium bro-
mide, acriflavine, and crystal violet), and quaternary ammonium
compounds (berberine, benzalkonium, and tetraphenylphospho-
nium chloride [TPP]). The YdhE-producing cells displayed a sim-
ilar drug susceptibility profile (with the exception of that to lome-
floxacin) as that of the NorM-producing E. coli cells, suggesting
that these two MATE transporters are functionally similar in vivo.
Like YdhE of E. coli, our drug susceptibility experiments
showed that NorM functions as a multidrug efflux pump when
it is expressed in E. coli. The MICs to 14 of the 24 antimicro-
bials (Table 1) were observed to increase by two- to eightfold
in NorM-producing AG100AX bacteria, which lack the AcrB
efflux pump. Similar differences (data not presented) in anti-
microbial susceptibility were obtained in AcrB E. coli TOP10
cells that were used to obtain recombinant NorM. In that the
MICs of norfloxacin, ciprofloxacin, enoxacin, and lomefloxacin
were raised in cells expressing NorM or YdhE, our results
suggest that, like other MATE transporters, such as BexA of
Bacteroides thetaiotaomicron (23), VcmA of Vibrio cholerae
(16), NorM of Vibrio cholerae (37) and AbeM of Acinetobacter
baumannii (40), fluoroquinolones might be a common sub-
strate for MATE transporters in the NorM cluster.
NorM and YdhE reduce drug accumulation in bacteria. The
observed (Table 1) capacity of NorM and YdhE to reduce the
susceptibility of E. coli to norfloxacin, ciprofloxacin, and ethidium
bromide is consistent with the drug recognition profiles of other
members of the MATE efflux transporter family. To confirm the
drug susceptibility testing results, we measured the levels of ac-
cumulation of norfloxacin and ethidium bromide in AG100AX
cells that carried pBADnorM, pBADydhE, or pBAD. The
results showed lower levels of norfloxacin (Fig. 1a) or ethidium
bromide (Fig. 1b) accumulation in AG100AX cells producing
NorM or YdhE compared to those in control cells harboring the
empty pBAD vector.
Members of the MATE family use energy from the proton
motive force (PMF) during export; and loss of the PMF inac-
tivates pump activity, resulting in the enhanced accumulation
of substrates, which translates to increased susceptibility to the
agents normally recognized by the transporter. Accordingly, we
also measured the levels of norfloxacin and ethidium bromide
accumulation after the addition of CCCP, a decoupler of the
membrane proton gradient. After the addition of CCCP into
the assay solution, the levels of accumulation of norfloxacin
(Fig. 1a) and ethidium bromide (Fig. 1b) increased drastically
in the NorM- and YdhE-expressing cells, with the levels of
accumulation being nearly the same in the three different
strains within 5 min. It should be noted that the effect of CCCP
is reversible simply by removing the CCCP and adding glucose
to reenergize the AG100AX cells. The experiments were per-
formed at least three times. Statistical comparisons were as-
sessed by Student’s t test, and P values of 0.05 were consid-
ered to indicate statistically significant differences (Fig. 1a
and b).
NorM expressed in E. coli behaves as an Na ion-dependent
transporter. It has been suggested but not proven that NorM of
N. gonorrhoeae is an Na-drug antiporter (32). Thus, we investi-
gated the levels of accumulation of ethidium bromide in isogenic
strains AG100AX/pBADnorM and AG100AX/pBAD in the
presence of Na or K. In AG100AX/pBADnorM cells, a
lower level of ethidium bromide accumulation was observed in
the presence of 100 mM NaCl than in the presence of 100 mM
KCl (Fig. 2a). In contrast, we did not observe a difference in the
levels of ethidium bromide accumulation in AG100AX/pBAD
cells, regardless of the presence of NaCl or KCl (Fig. 2b). Fur-
thermore, in the presence of NaCl, the level of accumulation of
TABLE 1. Drug susceptibility
Drug
MIC (g/ml)
AG100AX/
pBADnorM
AG100AX/
pBADydhE
AG100AX/
pBAD
Ethidium bromide 15.63 15.63 7.81
Ciprofloxacin 0.006 0.006 0.003
Rhodamine 6G 12.5 12.5 3.125
Chloramphenicol 0.625 0.625 0.625
TPP 25 25 12.5
Norfloxacin 0.032 0.016 0.008
Ofloxacin 0.013 0.013 0.013
Lomefloxacin 0.032 0.016 0.016
Tetracycline 1.25 1.25 1.25
Enoxacin 0.063 0.063 0.031
Doxorubicin 6.25 6.25 1.56
Benzalkonium 0.625 0.312 0.156
Novobiocin 3.125 3.125 1.56
Nalidixic acid 0.625 0.625 0.625
Crystal violet 2.5 2.5 0.625
CCCP 6.25 6.25 6.25
Rifampin 6.25 6.25 6.25
Streptomycin 	50,000 	50,000 	50,000
Methyl viologen 156.3 156.3 156.3
Vancomycin 250 250 250
Minocycline 0.625 0.625 0.625
Berberine 250 250 31.25
Acriflavine 7.82 7.82 3.91
Proflavine 12.5 12.5 6.25
Gentamicin 2.5 2.5 2.5
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ethidium bromide in the NorM-producing strain was lower than
that in AG100AX/pBAD.
We next measured the efflux of norfloxacin that had accu-
mulated in strain AG100AX/pBADnorM or AG100AX/
pBAD in the presence of Na or K. Cells were first loaded
with norfloxacin; thereafter, 100 mM either NaCl or KCl was
added to test the effect on drug efflux. As shown in Fig. 3a, the
addition of 100 mM NaCl to AG100AX/pBADnorM cells
resulted in a greater efflux of the drug from the cells compared
to the levels of efflux observed in the presence of KCl or
without added salt. This effect was NorM dependent because
the addition of either NaCl (100 mM) or KCl (100 mM) to
AG100AX/pBAD cells did not affect norfloxacin efflux (Fig.
3b). Taken together with the ethidium bromide accumulation
results, our observations support the earlier proposal (32) that
the gonococcal NorM protein is an Na-dependent trans-
porter.
In order to directly test whether efflux of an antimicrobial by
NorM is Na dependent, we then studied the extrusion of the
norfloxacin that had accumulated in AG100AX/pBADnorM
in the presence of CCCP. Cells were first loaded with norfloxa-
cin. Thereafter, different concentrations of NaCl (50 to 200
mM) were added to test their effects on drug efflux. All these
tests were done in the presence of 20 M CCCP. If NorM
requires proton ion as a coupler, then the level of norfloxacin
accumulated in the cell should not be reduced under these
conditions. However, if the coupling ion is Na, we should be
able to observe norfloxacin efflux in an [Na]-dependent man-
FIG. 1. NorM and YdhE reduce the levels of accumulation of norfloxacin and ethidium bromide in E. coli cells. (a) Accumulation of norfloxacin
in cells transformed by NorM (AG100AX/pBADnorM), YdhE (AG100AX/pBADydhE), or an empty vector (AG100AX/pBAD). CCCP was
added to the suspensions (first arrow) at a final concentration of 100 M. After 15 min, glucose was added (second arrow) at a final concentration
of 0.4%. (b) Accumulation of ethidium bromide in the same strains. CCCP was added to the suspensions (first arrow) at a final concentration of
100 M. After 15 min, glucose was added (second arrow) at a final concentration of 0.4%. , the values for AG100AX/pBADnorM and
AG100AX/pBADydhE cells were significantly different from those for the control (AG100AX/pBAD) (P  0.05).
FIG. 2. Sodium ion reduces the level of accumulation of ethidium bromide in cells transformed by NorM. (a) Accumulation of ethidium
bromide in AG100AX/pBADnorM cells after the addition of 100 mM NaCl or KCl; (b) accumulation of ethidium bromide in AG100AX/pBAD
cells (cells carrying the empty vector) after the addition of 100 mM NaCl or KCl. , the values of the ethidium bromide fluorescence intensity in
the presence of 100 mM NaCl were significantly different from those in the presence of 100 mM KCl (P  0.01).
VOL. 52, 2008 MATE EFFLUX PUMPS 3055
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ner. Figure 4 depicts the effect of Na on the extrusion of
norfloxacin. The experiment suggests that efflux activity was
stimulated by the Na ion. The addition of NaCl resulted in a
significant change in norfloxacin efflux. A previous study with
Pseudomonas aeruginosa PmpM, an H-dependent transporter
in the MATE family, indicated that the Na ion has no effect
on drug transport (11). Thus, it is highly likely that Na is the
coupling cation for NorM.
Our drug accumulation and efflux assays confirm the results
from an earlier report which suggested that NorM of N. gon-
orrhoeae is an Na-drug antiporter (32). First, Na was found
to enhance the ability of E. coli cells producing NorM to
maintain a lower level of accumulation of ethidium bromide
compared to the levels of accumulation by cells not producing
NorM, even in the presence of Na (Fig. 2). Hence, drug
export mediated by NorM of N. gonorrhoeae is driven by an
Na gradient. This export mechanism is also influenced by the
integrity of the PMF of the cytoplasmic membrane, since
CCCP, a proton conductor, could significantly enhance the
level of accumulation of ethidium bromide in NorM-producing
bacteria. These accumulation assays, however, provide indirect
evidence for efflux. Accordingly, direct support for efflux was
obtained in experiments that measured the level of norfloxacin
export by NorM-producing E. coli cells. The observed Na-
dependent capacity of NorM to mediate the export of nor-
floxacin (Fig. 3 and 4) provides direct evidence for this model.
Binding affinities of different drugs in vitro. The results of
the in vivo antimicrobial susceptibility tests (Table 1) and the
accumulation/efflux studies (Fig. 1 to 4) suggested that NorM
and YdhE recognize and export structurally diverse com-
pounds. Little is known, however, about the detail of substrate
binding by these MATE transporters. In order to directly test
the capacities of these proteins to bind to such diverse com-
pounds, we used a fluorescence polarization assay to quantify
the binding affinities of several compounds to NorM and YdhE
in vitro. This technique has been found to be sensitive and
precise enough and allows us to detect for the first time the
ligand binding of the E. coli AcrB multidrug efflux pump (an
RND transporter) in a detergent environment (39). As an
example of the results obtained by this protocol, Fig. 5a illus-
trates the binding isotherm of NorM in the presence of rho-
damine 6G. As presented in Fig. 5a, a simple hyperbolic curve
was observed for the binding of rhodamine 6G, and the KD was
3.4  0.2 M. A Hill plot of the data yielded a Hill coefficient
of 1.01  0.03 (Fig. 5b), suggesting a simple drug binding
process with a stoichiometry of one NorM monomer per rho-
damine 6G ligand. When the data were presented as a Scat-
chard plot (data not shown), it indicated a similar KD of 3.6 
0.1 M with no sign of heterogeneity in binding sites. In ad-
dition, the titration experiments indicated that YdhE binds to
FIG. 3. Sodium ion enhances norfloxacin efflux via NorM. (a) Norfloxacin efflux from AG100AX/pBADnorM cells carrying the norM gene
from N. gonorrhoeae; (b) norfloxacin efflux from AG100AX/pBAD cells carrying the empty vector. NaCl or KCl was added to the suspensions
(arrow) at a final concentration of 100 mM. , the values of norfloxacin fluorescence in the presence of 100 mM NaCl were significantly different
from those in the presence of 100 mM KCl (P  0.05).
FIG. 4. Effect of Na concentration on norfloxacin extrusion via
NorM. Norfloxacin efflux from AG100AX/pBADnorM cells carrying
the norM gene was measured in the presence of 0 to 200 mM NaCl. ,
the values of norfloxacin fluorescence in the presence of 50, 100, or 200
mM NaCl were significantly different from those in the absence of
NaCl (P  0.003), and the values of norfloxacin fluorescence in the
presence of 100 or 200 mM NaCl were significantly different from
those in the presence of 50 mM NaCl (P  0.01).
3056 LONG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 D
ecem
ber 3, 2015 by IO
W
A STATE UNIVERSITY
http://aac.asm
.org/
D
ow
nloaded from
 
rhodamine 6G with a KD of 3.0  0.2 M (Fig. 6a). This value
is comparable to that of NorM, suggesting that these two
transporters have similar affinities for this ligand. The Hill
plots (Fig. 6b) and the Scatchard plots (data not shown) of the
data indicated that the transporter employs a simple binding
stoichiometry of a 1:1 monomeric YdhE-to-rhodamine 6G mo-
lar ratio.
Fluorescence polarization assays were also employed to elu-
cidate the interaction of a variety of drugs with the NorM and
YdhE transporters. The titration experiments indicated that
NorM binds to ethidium bromide, proflavine, ciprofloxacin,
and norfloxacin with KDs of 12.3  1.3 M, 33.6  1.9 M,
121.3  15.7 M, and 105.6  9.8 M, respectively (Table 2).
These values are in the same range as those of YdhE, which
binds to ethidium bromide, proflavine, ciprofloxacin, and nor-
floxacin with KDs of 9.8  0.9 M, 22.1  0.9 M, 90.9  12.4
M, and 98.4  16.2 M, respectively (Table 2). This binding
was not affected by detergent, since similar KDs for the rhoda-
mine 6G-YdhE complex were obtained in reaction mixtures
that included 0.2%, 0.02%, and 0.0075% DDM.
To verify the validity of the fluorescence polarization assay,
we studied the binding affinity of rhodamine 6G to the purified,
detergent-solubilized YdhE efflux pump using equilibrium
dialysis. The dialysis data suggest a KD of 3.0  0.1 M, with
a stoichiometry of a 1:1 monomeric YdhE-to-ligand molar
ratio, for the binding of YdhE to rhodamine 6G (see Fig. S1 in
the supplemental material). This result is in good agreement
with that observed by the fluorescence polarization assay, in
which the KD of YdhE-rhodamine 6G is 3.0 M with a 1:1
binding stoichiometry. Apparently, NorM and YdhE bind to
these drugs with similar affinities. These values are similar to
the KD values for TPP binding in MdfA, an MF transporter,
and EmrE, an SMR transporter, as determined by radiola-
beled binding assays (19, 26), as well as the most recently
determined KDs for AcrB, an RND transporter, with four
different ligands, as determined by fluorescence polarization
assays (39).
The results from the fluorescence polarization and equilib-
rium dialysis assays suggest that NorM and YdhE use a binding
stoichiometry of a 1:1 monomeric transporter-to-ligand ratio.
Thus, it is very likely that these transporters employ a simple
drug binding process with no cooperativity. There is, however,
a possibility that drug molecules may bind to more than one
site in the proteins with similar affinities that may not be able
to be distinguished by these techniques. Further experiments
by different approaches may need to confirm this drug binding
stoichiometry.
pH dependence of drug binding to NorM. We performed
fluorescence polarization experiments to determine the bind-
ing of rhodamine 6G to NorM at different pH values. Figure 7
illustrates the decreases in the KD values for rhodamine 6G as
the pH increases from 5.8 to 8.5. Within this pH range, the KD
value decreases by about 2.6 M. This change is quite modest
compared with the effect of protons on the PMF-dependent
efflux pumps AcrB (39) and EmrE (26) in E. coli. The binding
affinities for drugs in these two transporters were strikingly
dependent on the pH. In the case of AcrB, within a pH range
from 5.5 to 8.4, the fluorescence polarization assay results
suggest that the change in KD for AcrB-rhodamine 6G reached
10.3 M. As NorM shows a pH-dependent profile very differ-
FIG. 5. Representative fluorescence polarization of NorM in 0.02% DDM with rhodamine 6G. (a) Binding isotherm of NorM with rhodamine
6G showing a KD of 3.4  0.2 M in buffer containing 20 mM HEPES–NaOH (pH 7.5) and 0.02% DDM. (b) Hill plot of the data obtained for
rhodamine 6G binding to NorM. , the fraction of bound rhodamine 6G. The plot gives a slope of 1.01  0.03, indicating a simple binding process
with no cooperativity. The interception of the plot provides a KD of 3.6  0.1 M for rhodamine 6G binding.
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ent from the profiles of the PMF-dependent pumps AcrB and
EmrE, it is very likely that NorM does not use H as an
energy-coupling ion. Since NorM tends to bind to positively
charged drugs, we expect that its drug-binding pocket should
consist of at least one acidic residue. Indeed, the protein se-
quence of NorM suggests that this transporter consists of two
negatively charged residues, Glu 261 and Asp 377, in the trans-
membrane region. These acidic residues could potentially form
the multidrug binding site. Thus, the modest pH effect on
NorM could be accounted for by the protonation state of the
acid residue(s) in the binding pocket.
Na dependence of drug binding to NorM. As the results of
in vivo studies of drug accumulation and efflux suggest, NorM
is a Na-dependent transporter, and the presence of Na ions
may affect the drug binding affinity in vitro. We therefore
investigated the Na dependence of drug binding using fluo-
rescence polarization. As shown in Fig. 8, the KD for rhoda-
mine 6G is Na dependent when the concentration of Na is
in the submicromolar range. In this region, the KD for rhoda-
mine 6G was a simple hyperbolic function of the Na concen-
tration. The curve showed saturability over 0.01 to 100 mM.
Like the pH effect, the change in KD for rhodamine 6G due to
the presence of the Na ion is quite small. Within 0 to 100 mM
Na, the change in KD reached only 2.5 M (Fig. 8). We also
added various concentrations of NaCl ranging from 100 to 400
mM (data not shown) and observed no significant change in
the KD.
FIG. 6. Representative fluorescence polarization of YdhE in 0.02% DDM with rhodamine 6G. (a) Binding isotherm of YdhE with rhodamine
6G showing a KD of 3.0  0.2 M in buffer containing 20 mM HEPES–NaOH (pH 7.5) and 0.02% DDM. (b) Hill plot of the data obtained for
rhodamine 6G binding to YdhE. , the fraction of bound rhodamine 6G. The plot gives a slope of 1.00  0.04, indicating a simple binding process
with no cooperativity. The interception of the plot provides a KD of 3.6  0.2 M for rhodamine 6G binding.
FIG. 7. Effect of pH on the KD of rhodamine 6G binding to NorM.
The resulting KDs were plotted against the pH.
TABLE 2. KDs and Hill coefficients of NorM and YdhE with five
different transported drugs
Drug
NorM YdhE
KD (M)
Hill
coefficient KD (M)
Hill
coefficient
Rhodamine 6G 3.4  0.2 1.01  0.03 3.0  0.2 1.00  0.04
Ethidium bromide 12.3  1.3 0.96  0.05 9.8  0.9 0.97  0.05
Profloxacin 33.6  1.9 0.94  0.03 22.1  0.9 1.02  0.01
Ciprofloxacin 121.3  15.7 1.08  0.06 90.9  12.4 1.09  0.06
Norfloxacin 126.3  11.3 1.06  0.03 98.4  16.2 1.14  0.05
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Competition binding of different drugs in YdhE. To confirm
that the drug molecules bind specifically in the YdhE trans-
porter, we performed competition experiments in which TPP
was titrated into a solution containing the preformed YdhE-
rhodamine 6G complex. In this case, TPP was chosen as a
second ligand to knock off the bound rhodamine 6G from
YdhE. The absorption spectra of TPP (from 200 to 600 nm)
showed that this molecule absorbs light at wavelengths of
224.9, 268.0, and 275.9 nm. At a  value of 527 nm, which is the
ex for rhodamine 6G, the energy is too low to excite TPP.
Thus, TPP was treated as a nonfluorescent ligand in the
“knock-off” experiments. The data revealed that TPP was able
to bind to YdhE and replace the bound rhodamine 6G mole-
cule from the protein, as demonstrated by the release of rho-
damine 6G observed from the reduction of polarization (Fig.
9). This binding assay provides direct evidence that TPP inter-
feres with the binding of rhodamine 6G, possibly by a direct
competitive binding process for the same binding site. Alter-
natively, the release of rhodamine 6G by TPP may be due to an
allosteric interaction between distinct binding sites of these
two ligands. Regardless, the titrations demonstrate that rho-
damine 6G is bound specifically in the YdhE transporter.
We have determined the binding affinities of five different
drugs to the purified, detergent-solubilized NorM and YdhE
proteins using fluorescence polarization assays. We note that
fluorescence polarization has been widely used to study pro-
tein-DNA interactions (12, 14, 18) and protein-ligand interac-
tions in transcriptional regulators (4, 34, 38). To our knowl-
edge, this is the first attempt to use this methodology to
investigate the interaction between MATE proteins and their
transported substrates. This approach also allows us, for the
first time, to quantify the strength of the transporter-drug in-
teraction among the MATE family of transporters.
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